fda spravato - Search News

FDA Approves ‘Spravato’ Nasal Spray

UPI News on MSN · 1d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

Hosted on MSN · 19m

FDA-Approved Nasal Spray For Depression Is First Of Its Kind

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called Spravato (esketamine),

FDA approves Spravato, nasal spray derived from Ketamine

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

J&J's Spravato gets another lift with new FDA approval

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Global Health Watch: Key Updates and Challenges

This summary covers the latest health-related news, including FDA's approval of Spravato as a standalone depression treatment ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results